AChE inhibitors for the treatment of Alzheimer’s disease became available generically from 2012, whereas NMDA receptor antagonists became available generically from 2014 (Table 2) [21]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.